EU warns of possible birth defect link to GSK's HIV drug

LONDON (Reuters) – Europe’s medicines regulator said it was assessing evidence that GlaxoSmithKline’s successful HIV drug dolutegravir might be linked to birth defects, adding it should not be prescribed to women seeking to become pregnant.

Source: Reuters Medical News

Leave a Reply

Your email address will not be published. Required fields are marked *